2C-B-BUTTERFLY

In this article, we will explore the topic of 2C-B-BUTTERFLY in depth, addressing its most relevant and current aspects. From its origins to its impact on today's society, through the different approaches and perspectives that have developed over time. This topic is of utmost importance today, since it has generated extensive debate and reflection in various areas, from politics to culture, and has marked a turning point in the way we address different problems. Throughout the development of this article, we will analyze the different aspects of 2C-B-BUTTERFLY, delving into its implications and generating a space for critical reflection around this phenomenon.
2C-B-BUTTERFLY
Clinical data
ATC code
  • none
Identifiers
  • 2-(10-Bromo-2,3,4,7,8,9-hexahydropyranochromen-5-yl)ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H18BrNO2
Molar mass312.207 g·mol−1
3D model (JSmol)
  • O3CCCc1c3c(Br)c2CCCOc2c1CCN
  • InChI=1S/C14H18BrNO2/c15-12-11-4-2-7-17-13(11)10(5-6-16)9-3-1-8-18-14(9)12/h1-8,16H2
  • Key:PAFZDNLBBBZEKE-UHFFFAOYSA-N

2C-B-BUTTERFLY (2C-B-MOTH, 2C-B-BFLY) is a conformationally-restricted derivative of the phenethylamine hallucinogen 2C-B, which was discovered in 1999 by Michael S. Whiteside and Aaron Monte. It is a ring-expanded homologue of the better known compound 2C-B-FLY, and has similar properties as an agonist for serotonin receptors, but with more selectivity for 5-HT2C over 5-HT2A.

Analogues and derivatives

Legal Status

2C-B-BUTTERFLY is illegal in Latvia.

See also

References

  1. ^ Whiteside MS (1999). "Synthesis of hexahydrobenzodipyrans as ring-expanded analogues of potent serotonin 5-HT2A/2C receptor probes". UW-LaCrosseJUR. 2: 61–68. CiteSeerX 10.1.1.688.4722.
  2. ^ Whiteside MS, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE, Monte A (October 2002). "Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes". Bioorganic & Medicinal Chemistry. 10 (10): 3301–6. doi:10.1016/S0968-0896(02)00209-2. PMID 12150876.
  3. ^ Schultz DM, Prescher JA, Kidd S, Marona-Lewicka D, Nichols DE, Monte A (June 2008). "'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines". Bioorganic & Medicinal Chemistry. 16 (11): 6242–51. doi:10.1016/j.bmc.2008.04.030. PMC 2601679. PMID 18467103.
  4. ^ "Explore N-(2C-B)-Fentanyl | PiHKAL · info". isomerdesign.com.
  5. ^ "Explore N-(2C-FLY)-Fentanyl | PiHKAL · info". isomerdesign.com.
  6. ^ Glennon, Richard A.; Bondarev, Mikhail L.; Khorana, Nantaka; Young, Richard; May, Jesse A.; Hellberg, Mark R.; McLaughlin, Marsha A.; Sharif, Najam A. (November 2004). "β-Oxygenated Analogues of the 5-HT2ASerotonin Receptor Agonist 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane". Journal of Medicinal Chemistry. 47 (24): 6034–6041. doi:10.1021/jm040082s. ISSN 0022-2623. PMID 15537358.
  7. ^ Beta-hydroxyphenylalkylamines and their use for treating glaucoma
  8. ^ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" [Regulations Regarding Narcotic Drugs, Psychotropic Substances and Precursors Controlled in Latvia]. Methodological Guidelines for the Application of Annex 1 to the Cabinet Regulation No. 847 (in Latvian). Ministry of Health of the Republic of Latvia. 8 November 2005. Archived from the original on 4 March 2016. Retrieved 8 October 2015.